Cumulative incidence of VTE within 12 months of treatment initiation stratified by risk groups derived from the PRISM score. The 12-month cumulative incidence of VTE in low-risk, intermediate-risk, and high-risk patients was 2.7% (95% CI, 0.7-7.0), 10.8% (95% CI, 8.2-13.8), and 36.5% (95% CI, 23.6-49.6), respectively.